CYP4V2
CYP4V2 is a gene in humans that encodes the Cytochrome P450 4V2 enzyme, a member of the Cytochrome P450 superfamily of enzymes. The proteins encoded by these genes are involved in the synthesis and metabolism of various molecules and chemicals within cells. Specifically, the CYP4V2 enzyme is involved in the metabolism of fatty acids, which are critical components of cell membranes and signaling molecules.
Function[edit | edit source]
The CYP4V2 enzyme plays a crucial role in the oxidation of fatty acids, a process essential for energy production and lipid metabolism. This enzyme is particularly involved in the metabolism of very long-chain fatty acids and eicosanoids, which are signaling molecules that mediate inflammatory responses and other physiological functions.
Clinical Significance[edit | edit source]
Mutations in the CYP4V2 gene have been associated with Bietti's Crystalline Dystrophy (BCD), a rare genetic disorder that affects the retina and can lead to progressive vision loss. Patients with BCD typically present with crystalline deposits in the retina, followed by atrophy of the retinal pigment epithelium and choroid, leading to night blindness and loss of peripheral vision. The exact mechanism by which mutations in CYP4V2 lead to BCD is not fully understood, but it is believed to involve disruptions in lipid metabolism within the eye.
Genetic Studies[edit | edit source]
Studies have identified several mutations in the CYP4V2 gene that are linked to Bietti's Crystalline Dystrophy. These mutations can lead to a loss of function of the CYP4V2 enzyme, disrupting the normal metabolism of fatty acids and possibly leading to the accumulation of toxic lipid metabolites in the eye.
Treatment and Management[edit | edit source]
There is currently no cure for Bietti's Crystalline Dystrophy, and treatment focuses on managing symptoms and slowing the progression of the disease. This may include the use of low vision aids and, in some cases, supportive therapies such as vitamin A supplementation, though the efficacy of such treatments can vary among individuals.
Research Directions[edit | edit source]
Research into CYP4V2 and its role in Bietti's Crystalline Dystrophy is ongoing, with studies aimed at understanding the precise mechanisms by which mutations in the gene affect lipid metabolism and eye health. There is also interest in developing gene therapy approaches to treat BCD by correcting the underlying genetic defect in CYP4V2.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD